Cognizant Updates FY26 Guidance

Regeneron Pharmaceuticals

549.27 CHF -0.92%

• Charts
• News
• Analysen

Kaufen Verkaufen

(RTTNews) - Cognizant (CTSH) said its 2026 adjusted operating margin guidance is increased to 16.0% to 16.2%, year-over-year expansion of 20 to 40 basis points compared to prior guidance of 10 to 30 basis points of expansion. Constant currency revenue growth guidance is unchanged at 4.0% to 6.5%. Full-year 2026 adjusted EPS is expected to be in the range of $5.63 to $5.77, growth of 7% to 9%. The company expects second quarter revenue to be $5.45 to $5.52 billion, growth of 3.8% to 5.3%, or 3.2% to 4.7% in constant currency.

First quarter net income was $662 million compared to $663 million, prior year. EPS was $1.39, increased 3.7% year-over-year. Adjusted EPS was $1.40 increased 13.8%. Adjusted Operating Margin was 15.6%, increased 10 basis points year-over-year. Revenue was $5.4 billion, up 5.8% from last year, or 3.9% in constant currency.

In pre-market trading on NasdaqGS, Cognizant shares are down 4.75 percent to $52.50.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.